[(177)Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial. (linkinghub.elsevier.com)

Authors: Walter T … Capdevila J Journal: The Lancet Published: 2026-07-02 DOI: https://doi.org/10.1016/S0140-6736(26)00604-5